Hints and tips:
...Two doses of the BioNTech/Pfizer vaccine provide 70 per cent protection against being admitted to hospital with the Omicron coronavirus variant, according to the first real-world analysis of protection against...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Companies have lost hundreds of millions of dollars in failed trials, leading some such as Pfizer and Sanofi to drop out of the race. Others have doubled-down....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...You may wish to explore general management programmes v specialising....
...These include UK/Prussia v France at Waterloo in 1815, UK/France v Germany between 1914 and 1918 and France/Germany v UK in Brussels ever since 1973....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Oliver Brandicourt of the drug group’s primary care unit, Ruth McKernan, head of Pfizer’s Sandwich site, Rod MacKenzie of worldwide research and Pfizer UK managing director Richard Blackburn faced the grilling...
...In December, Jeff Kindler, chief executive of Pfizer, abruptly resigned....
...Charlotte Clarke...
...“There have been a lot [of product launches] under Kraft, for example the Spots v Stripes Challenge Bar as part of the Olympic campaign,” he says....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...And economists at investment banks have proven especially tetchy – Alan Clarke at BNP Paribas and Michael Saunders at Citigroup spring to mind....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition